Other regions of copy number change demonstrate genomic gains in the region of c-Myc and losses in the region of p16 (INK4a, CDNK2A) in recurrent or non-survivor tumours, supporting a prognostic association of the Myc:CDNK2A ratio in NSCLC, as has been described in head and neck SCC [46]. This evidence concerns the gene MYC and neoplasm.